Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Bristol-Myers Squibb’s ImClone Takeover Bid A Preemptive Grab?

This article was originally published in The Pink Sheet Daily

Executive Summary

BMS takeover bid may be aimed at thwarting a spin-off, controlling potential Erbitux competition.

You may also be interested in...



Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder

Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.

Mystery Date: ImClone Rejects Bristol For Unnamed $70 Per Share Bidder

Much industry speculation suggests Icahn seeks higher bid from BMS, which initially offered $60 per share.

PDL Deal Adds To BMS’ Chips In Multiple Myeloma

Phase I antibody represents novel, targeted approach in a busy space.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel